Pneumocystis carinii pneumonia and pentamidine prophylaxis - Tips from Other Journals

Date: Sept, 1991

Murphy and associates performed a double-blind, randomized trial to evaluate the efficacy and safety of three different dosages of pentamidine for prophylaxis against Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome.

A total of 175 patients with AIDS were randomly assigned to receive 5 mg, 60 mg or 120 mg of aerosol pentamidine biweekly. All of the patients had a previous episode of P. carinii pneumonia. After 24 weeks of therapy, patients entered a second phase of the trial; in this part of the study, the patients receiving 5 mg of pentamidine were randomized to receive either 60 mg or 120 mg.

Significantly more relapses of P. carinii pneumonia occurred in the patients receiving 5 mg of pentamidine than in those receiving either 60 mg or 120 mg. Also, patients receiving the higher doses had fewer relapses when compared with historic controls. No differences in efficacy or safety were found between the 60-mg dosing regimen and the 120-mg dosing regimen in patients followed for at least 52 weeks. Side effects were generally mild.

The authors conclude that biweekly administration of 60 mg or 120 mg of pentamidine significantly decreases recurrence of P. carinii pneumonia in patients with AIDS. (American Journal of Medicine, April 1991, vol. 90, p. 418.)

COPYRIGHT 1991 American Academy of Family PhysiciansCOPYRIGHT 2004 Gale Group

 
© 2006, DrPlace.com, All Rights Reserved.